BioMarin Announces Selection of NAGLU, BMN 250 for the Treatment of Sanfilippo B

BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)

Please click here for the full BioMarin News Release

This entry was posted in News, Uncategorized. Bookmark the permalink.

Comments are closed.